ACXP - Company ID 0001736243
The table below shows Acurx Pharmaceuticals, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$6.79M | -$10.38M | -$9.80M | -$7.54M | -$5.01M | -$3.35M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | - | - | - | - | - | - |
| Dividends paid | - | - | - | - | - | - |
Acurx Pharmaceuticals, Inc. reported operating cash flow of -$6.79M for fiscal year 2025. That is up 34.6% from -$10.38M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$3.35M (FY 2020) to -$6.79M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $10.64M | $6.62M | $8.16M | $3.70M | $14.80M | $4.04M |